Tango Therapeutics, Inc. (NASDAQ:TNGX – Get Free Report) insider Adam Crystal sold 27,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $22.87, for a total transaction of $617,490.00. Following the completion of the transaction, the insider owned 115,743 shares of the company’s stock, valued at $2,647,042.41. This represents a 18.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Adam Crystal also recently made the following trade(s):
- On Friday, May 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.23, for a total transaction of $573,210.00.
- On Wednesday, April 15th, Adam Crystal sold 38,460 shares of Tango Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $961,500.00.
- On Wednesday, April 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.20, for a total transaction of $572,400.00.
- On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $20.11, for a total transaction of $241,320.00.
- On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The shares were sold at an average price of $15.00, for a total transaction of $303,765.00.
Tango Therapeutics Trading Down 0.1%
Shares of NASDAQ TNGX opened at $21.47 on Thursday. Tango Therapeutics, Inc. has a twelve month low of $2.96 and a twelve month high of $28.41. The company has a market capitalization of $3.11 billion, a price-to-earnings ratio of -25.87 and a beta of 1.19. The firm has a 50-day moving average of $22.39 and a two-hundred day moving average of $15.48.
Analyst Upgrades and Downgrades
A number of analysts have commented on TNGX shares. Guggenheim upped their price objective on shares of Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, March 6th. B. Riley Financial reaffirmed a “buy” rating on shares of Tango Therapeutics in a research note on Friday, March 27th. UBS Group set a $55.00 price objective on shares of Tango Therapeutics in a research note on Thursday, May 14th. Mizuho upped their price objective on shares of Tango Therapeutics from $20.00 to $30.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Finally, Wall Street Zen lowered shares of Tango Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $32.27.
Read Our Latest Research Report on TNGX
Institutional Trading of Tango Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. Global Retirement Partners LLC acquired a new stake in Tango Therapeutics in the fourth quarter valued at approximately $35,000. Dynamic Technology Lab Private Ltd lifted its stake in Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock valued at $35,000 after acquiring an additional 15,037 shares during the last quarter. Legal & General Group Plc lifted its stake in Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after acquiring an additional 1,640 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Tango Therapeutics by 148,800.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after acquiring an additional 4,464 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in Tango Therapeutics in the fourth quarter valued at approximately $40,000. 78.99% of the stock is currently owned by hedge funds and other institutional investors.
Tango Therapeutics Company Profile
Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.
Featured Articles
- Five stocks we like better than Tango Therapeutics
- As AI Data Breaches Become More Common, This Cybersecurity ETF Is SurgingAI
- Coke’s $10B India IPO Plan Pops the Top on Hidden Value
- FedEx Unboxes Billions in Post-Spinoff Value
- Marvell’s AI Moment Raises a Bigger Question for Amazon and ServiceNow
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
